Abstract: Methods of treating autoimmune microvascular conditions using diosmin or diosmetin are described, particularly the treatment of digital ulcers in systemic sclerosis.

Abstract: Methods of treating autoimmune microvascular conditions using diosmin or diosmetin are described, particularly the treatment of digital ulcers in systemic sclerosis.

Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Abstract: Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.

Abstract: Provided is a formulation and a method associated therewith for treating inflammation. The formulation includes therapeutically effective amounts of curcuminoids and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2?, 3?, 4?, 5?, or 6? modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2?, 3?, 4?, 5?, or 6? modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Abstract: The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2?, 3?, 4?, 5?, or 6? modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2?, 3?, 4?, 5?, or 6? modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.

Abstract: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.